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Abstract We examined the structure^activity relationship of
cloned lysophosphatidic acid (LPA) receptors (endothelial cell
differentiation gene (EDG) 2, EDG4, and EDG7) by measuring
[Ca2+]i in Sf9 insect cells expressing each receptor using LPA
with various acyl chains bound at either the sn-1 or the sn-2
position of the glycerol backbone. For EDG7 the highest
reactivity was observed with LPA with v9-unsaturated fatty
acid (oleic (18:1), linoleic (18:2), and linolenic (18:3)) at sn-2
followed by 2-palmitoleoyl (16:1) and 2-arachidonoyl (20:4)
LPA. In contrast, EDG2 and EDG4 showed broad ligand
specificities, although EDG2 and EDG4 discriminated between
14:0 (myristoyl) and 16:0 (palmitoyl), and 12:0 (lauroyl) and
14:0 LPAs, respectively. EDG7 recognizes the cis double bond at
the v9 position of octadecanoyl residues, since 2-elaidoyl (18:1,
trans) and 2-petroselinoyl (18:1, cis-v12) LPA were poor ligands
for EDG7. In conclusion, the present study demonstrates that
each LPA receptor can be activated differentially by the LPA
species. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycero-3-
phosphate) is a lipid mediator with diverse biological proper-
ties [1,2]. It activates platelet aggregation, induces contraction
of smooth muscle cells and retraction of neurites, and stim-
ulates cell chemotaxis. It also has a mitogenic e¡ect on the cell
cycle. LPA also elicited various cellular responses including
stimulation of phospholipases, mobilization of intracellular
Ca2, stimulation or inhibition of adenylate cyclase, activa-
tion of the mitogen-activated protein (MAP) kinase cascade,
and cytoskeleton rearrangement by activation of small
GTPase Rho [1,2].
It has been demonstrated that speci¢c G protein-coupled
receptors (GPCRs) present in many types of cells mediate
the cellular e¡ects of LPA. So far, at least three GPCRs be-
longing to the EDG (endothelial cell di¡erentiation gene) fam-
ily, EDG2/LPA1/vzg-1 [3], EDG4/LPA2 [4], and EDG7/LPA3
[5], have been identi¢ed as cellular receptors for LPA. These
GPCRs share 50^54% identical amino acids, and may couple
with di¡erent G proteins. EDG2 is most associated with acti-
vation of the Gi pathway that leads to inhibition of adenylate
cyclase [3], while EDG4 and EDG7 are associated most prom-
inently with the Gq=11 pathways mediating Ca2 signaling
(EDG4 and EDG7) [4^6], and activation of a serum response
element reporter gene and MAP kinase (EDG4) [4,5].
LPA occurs naturally as an albumin-bound serum factor
generated during blood clotting from activated platelets [7].
It also accumulates in various biological £uids including se-
rum, aged plasma, and ascites induced by ovary tumors [8]. In
activated platelets, several molecular species of LPA with sa-
turated (stearoyl (18:0), palmitoyl (16:0)) or unsaturated
(oleoyl (18:1), linoleoyl (18:2), arachidonoyl (20:4)) acyl
chains have been detected [9,10]. These diverse fatty acid moi-
eties may be linked to either the sn-1 or the sn-2 position of
the glycerol backbone. In addition, a small portion of natural
glycerophospholipids contain an ether linkage at the sn-1 po-
sition rather than an ester bond (1-alkyl-2-lyso-sn-glycero-3-
phosphate and 1-alkenyl-2-lyso-sn-glycero-3-phosphate (alkyl-
and alkenyl-GP)) [11,12]. Thus, various molecular species of
LPA or LPA-like lipids (LPA analogs) are present in vivo. It
appears that the structure^activity relationship of these LPA
and LPA analogs depends on cells and tissues [13^19]. In
these studies, the length, degree of unsaturation, and linkage
to the glycerol backbone of fatty acyl chains modulate the
activity of LPA in a di¡erent way when comparing various
biological responses including platelet aggregation [13,14], cal-
cium mobilization in A431 cells [15], proliferation of rat-1
¢broblasts [16] and cultured vascular smooth muscle cells
[17], activation of serum response element-regulated genes
[18], and vasoactive e¡ects of LPA [19]. These di¡erential
responses can be explained by the di¡erential expression of
each LPA receptor, since our previous study clearly indicated
that EDG4 and EDG7 had quite distinct ligand speci¢cities
[5]. In this study, as a part of our continuing studies to char-
acterize each LPA receptor, we investigated the structure^ac-
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tivity relationship of various LPA and LPA analogs using
LPA non-responding Sf9 insect cells expressing each cloned
LPA receptor by measuring intracellular Ca2 mobilization.
2. Materials and methods
2.1. Lipids
L-K-Dioleoyl-phosphatidylcholine (PC) (18:1, cis-v9-octadecenoic
acid), L-K-dilinoleoyl-PC (18:2, cis,cis-v9,v12-octadecadienoic acid),
L-K-dilinolenoyl-PC (18:3, all cis-v9,v12,v15-octadecatrienoic acid), L-
K-diarachidonoyl-PC (20:4, all cis-v5,v8,v11,v14-eicosatetraenoic
acid), L-K-dimyristoyl-PC (14:0), L-K-dipalmitoyl-PC (16:0), L-K-dis-
tearoyl-PC (18:0), L-K-palmitoleoyl-PC (16:1, cis-v9-hexadecenoic
acid), L-K-dipetroselinoyl-PC (18:1, cis-v12-octadecenoic acid), L-K-
dielaidoyl-PC (18:1, trans-v9-octadecenoic acid), and egg yolk phos-
phatidic acid (PA) were purchased from Avanti Polar Lipids (Alabast-
er, AL, USA). Platelet-activating factor (PAF, C18:1 cis) was pur-
chased from Biomol Research Laboratories, Inc. Bovine brain
phosphatidylethanolamine (PE) plasmalogen was purchased from
Doosan Serdary Research Laboratories (Toronto, Ont., Canada).
PA was prepared from PC according to the method described by
Satouchi et al. [20] using phospholipase D from Actinomadura (kindly
donated by Meito Sangyo, Tokyo, Japan). LPA with various acyl
chains was prepared enzymatically from the corresponding PC by
reacting the lipids sequentially with phospholipase D and phospholi-
pase A1 or A2 as previously described [5]. Alkyl-GP was prepared
from PAF (C18:1 cis) by reacting the lipid sequentially with phos-
pholipase D and a recombinant brain PAF acetylhydrolase (K2 sub-
unit) [21]. Alkenyl-GP was prepared from bovine brain PE plasmal-
ogen by using phospholipase D and phospholipase A2. All lipids were
dissolved in chloroform:methanol (2:1, v:v) and dissolved in MBS
(see below) containing 0.1% fatty acid-free bovine serum albumin
(Sigma) after the organic solvent had been removed by evaporation.
2.2. Construction of cDNA for EDG2-EDG4 chimeric receptor
The carboxy-terminal intracellular domain of EDG2 (amino acids
315^355) was replaced with that of EDG4 (amino acids 298^351). The
chimeric cDNA was constructed as follows: a cDNA fragment encod-
ing the N-terminus, seven transmembrane and intracellular domains
Fig. 1. Chemical structure of LPA and its structural analogs. A^K: Chemical structure of fatty acids used in this study, which are linked to ei-
ther the sn-1 or sn-2 position of LPA. The chemical structure of the LPA analogs alkyl-GP and alkenyl-GP is shown in L.
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of EDG2 (amino acids 1^314) was generated by PCR using FLAG-
EDG2 pFASTBAC as template DNA and the following two oligonu-
cleotides: ATGCGTCGACATGGACTACAAAGACGATGACGA-
TAAAGCTGCCATCTCTACTTCCATCCCT, and GGTGCGGC-
GCATCTCAGCATCTCGGTAGGAGTAAATGATGGGGTTCAT.
The cDNA encoding the C-terminal intracellular domain of EDG4
was generated by PCR using FLAG-EDG4 pFASTBAC1 as template
DNA and the following two oligonucleotides: ATGAACCCCAT-
CATTTACTCCTACCGAGATGCTGAGATGCGCCGCACC, and
ATGCGCGGCCGCTCAGTCCTGTTGGTTGGGTTGAGC. The
resulting 1000-bp (encoding amino acids 1^314 of EDG2) and 300-
bp (encoding the C-terminal domain of EDG4) PCR fragments were
puri¢ed by agarose gel electrophoresis. The two DNA fragments were
mixed, denatured at 94‡C, and annealed on ice. Finally, using this
annealed DNA as template DNA, an EDG2-EDG4 chimera receptor
cDNA was generated by PCR using the following oligonucleotides:
ATGCGTCGACATGGACTACAAAGACGATGACGATAAAGC-
TGCCATCTCTACTTCCATCCCT, and ATGCGCGGCCGCTCA-
GTCCTGTTGGTTGGGTTGAGC. The resulting DNA fragment
(1.3 kb) was digested by SalI/NotI and ligated into pFASTBAC1,
and baculoviruses were prepared as described [5]. DNA sequences
of cDNAs prepared by PCR were con¢rmed by DNA sequencing.
Cloning and characterization of human EDG4 cDNA was ¢rst re-
ported by An et al. [4]. We also cloned a cDNA for human EDG4
by the RT-PCR method [5]. We recently found that our cDNA has a
one-base insertion in the 3P region encoding the C-terminal domain,
which results in a di¡erent amino acid sequence in the EDG4 C-
terminal region. We also found that the nucleotide sequence of human
EDG4 deposited in the EST database (GenBank accession number
W60555) matched our sequence. The amino acid sequence of the
EDG4 C-terminal region used in the chimeric receptor, in which the
di¡erent amino acid from original human EDG4 [4] is shown in
italics, is as follows: RDAEMRRTFRRLLCCACLRQSTRESVH-
YTSSAQGGASTRIMLPENGHPLMDSTL (amino acid positions
298^351). The nucleotide sequence data of our EDG4 have been sub-
mitted to the GenBank database under the accession number
AF233092.
2.3. Baculovirus system
Sf9 insect cells were grown in serum-free EX-CELL420 insect cell
medium (Nichirei, Tokyo, Japan) at 27‡C. For infection, 6U105 cells/
ml were mixed with recombinant or wild-type Autographa californica
nuclear polyhedrosis virus to produce a multiplicity of infection of 10
and incubated for 48 h at 27‡C. Expression of the FLAG-tagged
protein was con¢rmed by immuno£uorescence using an anti-FLAG
monoclonal antibody (M5; Eastman Kodak Company, New Haven,
CT, USA).
2.4. Ca2 measurements
Sf9 cells were harvested 48 h after baculovirus infection, washed
gently with morpholinoethanesulfonic acid-bu¡ered saline (MBS) con-
taining 10 mM NaCl, 60 mM KCl, 17 mM MgCl2, 10 mM CaCl2, 110
mM sucrose, 4 mM glucose, 0.1% fatty acid-free bovine serum albu-
min (Sigma), and 10 mM morpholinoethanesulfonic acid, pH-adjusted
to 6.2 at room temperature with Tris, and loaded with 2 mM Fura-2
acetoxymethyl ester (Fura-2 AM; Molecular Probes Inc., Eugene,
OR, USA) for 45 min. Free Fura-2 AM was washed out, and the
cells were resuspended in the HBS bu¡er to produce a concentration
of 106 cells/ml. Agonist-induced Fura-2 AM £uorescence of samples
in quartz cuvettes kept at 27‡C was monitored at excitation wave-
lengths of 340 and 380 nm and an emission wavelength of 500 nm
using a CAF-110 spectro£uorimeter (Japan Spectroscopy, Inc., To-
kyo, Japan). Fluorescence was recorded before and after addition of
LPAs.
Fig. 2. The activities of LPA and its structural analogs to induce increases in [Ca2]i in EDG4-expressing Sf9 cells. EDG4-expressing Sf9 cells,
loaded with Fura-2 AM, were stimulated with 22 compounds of LPA and its analogs, and changes in [Ca2]i were analyzed in CAF-110. The
open and closed circles in A^K represent 1-acyl- and 2-acyl-LPA, respectively. A, Oleoyl (18:1, cis-v9-octadecenoic acid); B, linoleoyl (18:2,
cis,cis-v9,v12-octadecadienoic acid); C, linolenoyl (18:3, all cis-v9,v12,v15-octadecatrienoic acid); D, arachidonoyl (20:4, all cis-v5,v8,v11,v14-ei-
cosatetraenoic acid); E, lauroyl (12:0); F, myristoyl (14:0); G, palmitoyl (16:0); H, stearoyl (18:0); I, elaidoyl (18:1, trans-v9-octadecenoic
acid); J, palmitoleoyl (16:1, cis-v9-hexadecenoic acid); K, petroselinoyl (18:1, cis-v12-octadecenoic acid) LPA. L, 1-O-alkyl (18:1, cis-v9-octade-
cenoic acid)-2-lyso-sn-glycero-3-phosphate (closed triangle) and 1-alkenyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP) from bovine brain (open
square).
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3. Results
We chose the insect Sf9 cells and expressed each LPA re-
ceptor in the cells since they did not show any Ca2 responses
to LPA, although in almost all types of mammalian cells
tested, LPA induces a rapid increase in the [Ca2]i. The
EDG4 and EDG7 receptors expressed in the Sf9 cells trans-
duced the Ca2 response by LPA, whereas EDG2 did not up
to 10 WM of 1-oleoyl LPA [5]. Fig. 1 gives the structure of the
various LPAs and analogs used in the present study. To ex-
amine how the nature, length, linkage, and position of the
acyl chain a¡ect the potency of LPA in each cloned LPA
receptor, we tested LPA species with di¡erent acyl chain
lengths, varying degrees of unsaturation at either the sn-1 or
the sn-2 position, and LPA analogs with di¡erent linkage of
the side chain (ester or ether bonds).
3.1. Structure^activity relationship of EDG4
We ¢rst examined the ligand speci¢city of EDG4. From the
dose^response curves in Fig. 2 and the EC50 values in Table 1,
it is evident that all acyl-LPAs tested with saturated or unsat-
urated fatty acids at either the sn-1 or the sn-2 position, except
for lauroyl (12:0) LPA, showed almost equal potency to
EDG4. The Ca2 response was detectable at as low as 0.1
nM and augmented with increased concentration of ligands.
The EC50 values were about 10 nM. As shown in Fig. 4, alkyl-
Table 1
EC50 values of LPA species and its structural analogs
Compound EDG2 EDG4 EDG7
LPA
1-Oleoyl V200 nM V10 nM V75 nM
2-Oleoyl V200 nM V10 nM V10 nM
1-Linoleoyl V200 nM V10 nM V80 nM
2-Linoleoyl V200 nM V10 nM V10 nM
1-Linolenoyl V200 nM V10 nM V80 nM
2-Linolenoyl V200 nM V10 nM V10 nM
1-Arachidonoyl V200 nM V10 nM V1.0 WM
2-Arachidonoyl V200 nM V10 nM V100 nM
1-Lauroyl s 50 WM s 50 WM s 50 WM
2-Lauroyl s 50 WM s 50 WM s 50 WM
1-Myristoyl s 50 WM V50 nM s 50 WM
2-Myristoyl s 50 WM V50 nM s 25 WM
1-Palmitoyl V400 nM V10 nM s 50 WM
2-Palmitoyl V400 nM V10 nM s 25 WM
1-Stearoyl V800 nM V100 nM s 50 WM
2-Stearoyl V800 nM V100 nM s 25 WM
1-Elaidoyl V800 nM V50 nM s 50 WM
2-Elaidoyl V800 nM V50 nM s 25 WM
1-Palmitoleoyl V200 nM V10 nM s 25 WM
2-Palmitoleoyl V200 nM V10 nM V100 nM
1-Petroselinoyl V200 nM V10 nM s 50 WM
2-Petroselinoyl V200 nM V10 nM s 25 WM
LPA analogs
Alkyl-GP V2 WM V1.0 WM V6.0 WM
Alkenyl-GP V2 WM V1.0 WM s 25 WM
Fig. 3. The activities of LPA and its structural analogs to induce increases in [Ca2]i in EDG7-expressing Sf9 cells. EDG7-expressing Sf9 cells,
loaded with Fura-2 AM, were stimulated with 22 compounds of LPA and its analogs, and changes in [Ca2]i were analyzed in CAF-110. The
open and closed circles in A^K represent 1-acyl- and 2-acyl-LPA, respectively. A, Oleoyl (18:1, cis-v9-octadecenoic acid); B, linoleoyl (18:2,
cis,cis-v9,v12-octadecadienoic acid); C, linolenoyl (18:3, all cis-v9,v12,v15-octadecatrienoic acid); D, arachidonoyl (20:4, all cis-v5,v8,v11,v14-ei-
cosatetraenoic acid); E, lauroyl (12:0); F, myristoyl (14:0); G, palmitoyl (16:0); H, stearoyl (18:0); I, elaidoyl (18:1, trans-v9-octadecenoic
acid); J, palmitoleoyl (16:1, cis-v9-hexadecenoic acid); K, petroselinoyl (18:1, cis-v12-octadecenoic acid) LPA. L, 1-O-alkyl (18:1, cis-v9-octade-
cenoic acid)-2-lyso-sn-glycero-3-phosphate (closed triangle) and 1-alkenyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP) from bovine brain (open
square).
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and alkenyl-GP also activated EDG4. However, both of them
were weaker ligands than acyl-LPAs by several tens of times.
3.2. Structure^activity relationship of EDG7
In marked contrast to EDG4, EDG7 showed quite di¡erent
ligand speci¢city (Fig. 3, Table 1). 1- and 2-lauroyl (12:0)
LPA did not induce any detectable Ca2 response at concen-
trations up to 10 WM in Sf9 cells expressing EDG7 (Fig. 3E).
In addition 1-myristoyl (14:0), 1-palmitoyl (16:0), and 1-
stearoyl (18:0) LPA were also very poor agonists against
EDG7. By contrast, 2-myristoyl, 2-palmitoyl, and 2-stearoyl
LPA were capable of inducing a Ca2 response in the cells,
although a relatively higher concentration (1^10 WM) of li-
gands was required (Fig. 3F^H). Among 1-acyl- and 2-acyl-
LPA containing unsaturated fatty acids, 2-oleoyl (18:1, cis-v9-
octadecenoic acid), 2-linoleoyl (18:2, cis,cis-v9,v12-octadeca-
dienoic acid), and 2-linolenoyl (18:3, all cis-v9,v12,v15-octade-
catrienoic acid) were the most potent ligands for EDG7 (Fig.
3A^C). The EC50 values of the three acyl-LPA were about
5 nM. 2-Arachidonoyl (20:4, all cis-v5,v8,v11,v14-eicosatetrae-
noic acid, Fig. 3D) and 2-palmitoleoyl (16:1, cis-v9-hexadece-
noic acid, Fig. 3J) LPA followed next (EC50 values about 80
nM). When the activities of 1-acyl- and 2-acyl-LPA with the
same acyl chain were compared, 2-acyl-LPAs always showed
approximately 10 times higher activity. We next investigated
which structural features of LPA are important for EDG7. As
shown in Fig. 3, elaidoyl LPA (18:1, trans-v9-octadecenoic
acid, Fig. 3I) and petroselinoyl LPA (18:1, cis-v12-octadece-
noic acid, Fig. 3K) were very weak agonist for EDG7,
although 2-acyl isomers showed higher activity than 1-acyl
isomers (Fig. 3I,K). Both alkyl-GP and alkenyl-GP were
again not good ligands for EDG7 (Fig. 3L).
3.3. EDG2-EDG4 chimeric receptor transduces Ca2+ response
in Sf9 cells
We have not been able to test the ligand speci¢city of
EDG2 using the baculovirus system, since EDG2 expressed
in Sf9 cells did not mediate Ca2 response (Fig. 4A), possibly
due to a lack of G protein coupled to EDG2 in the insect cells
[5]. Generally, the intracellular C-terminal domains of GPCR
are responsible for coupling to G proteins. Accordingly, we
constructed EDG2-EDG4 chimeric receptors, in which the
intracellular C-terminal amino acids of EDG2 were replaced
with those of EDG4, and examined the Ca2 response in Sf9
cells. As shown in Fig. 4, the chimeric receptors transduced
the Ca2 response by LPA in Sf9 cells. The chimeric receptor
may retain the ligand speci¢city of EDG2, because it is gen-
erally accepted that the ligand recognition domain of GPCR
resides in the seventh transmembrane domain. We therefore
used EDG2-EDG4 chimeric receptor to examine the struc-
ture^activity relationship of LPA for EDG2.
3.4. Structure^activity relationship of EDG2-EDG4 chimeric
receptor
Apparently, the ligand speci¢city of the EDG2-EDG4 chi-
meric receptor is similar to that of EDG4, although myristoyl
(14:0) LPA induced a very little response (Fig. 5F, Table 1).
Lauroyl (12:0) LPA failed to activate EDG2 (Fig. 5E). Like
EDG4, the EDG2-EDG4 chimeric receptor did not distin-
guish 1- and 2-acyl isomers. It is also evident that the a⁄nity
of the chimeric receptor to the ligand was considerably lower
than the other LPA receptors (Fig. 5, Table 1). EC50 values of
acyl-LPAs for EDG2-EDG4 chimeric receptors were about
200^800 nM. Both alkyl- and alkenyl-GP were weaker ligands
toward the chimeric receptor as well (Fig. 5, Table 1).
4. Discussion
In the present study, we focused on the ligand speci¢city of
EDG7 and further identi¢ed molecular features of LPA re-
Fig. 4. EDG2-EDG4 chimeric receptor transduces the Ca2 re-
sponse by LPA in Sf9 cells. Ca2 response of Sf9 cells infected with
EDG2 (A) and EDG2-EDG4 chimeric receptor (B and C) baculovi-
ruses by LPA. Sf9 cells were infected with each baculovirus, loaded
with the £uorescent Ca2 indicator Fura-2 AM, and stimulated with
1 (B) or 10 WM 1-oleoyl LPA (A and C).
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quired for not only EDG7 but also EDG4. In addition we
examined the ligand speci¢city of EDG2 using the EDG2-
EDG4 chimeric receptor. The ligand speci¢city of EDG7 pre-
sented in this study strongly indicates that the endogenous
ligand for EDG7 is 2-acyl LPA with unsaturated fatty acids
such as oleic, linoleic, and linolenoic acids, all of which have a
cis-double bond at the v9 position (Fig. 3, Table 1). 2-Arach-
idonoyl (20:4, all cis-v5,v8,v11,v14-eicosatetraenoic acid) LPA
was a weaker ligand for EDG7. This is a reasonable result
because the double bond at the v9 position in a cis con¢gu-
ration is not present in arachidonic acid. 2-Palmitoleoyl (16:1,
cis-v9-hexadecenoic acid) is a weaker ligand than 2-oleoyl
LPA. In addition 2-elaidoyl LPA was a poor agonist for
EDG7. In conclusion, the double bond at the v9 position in
the cis con¢guration and the length of the carbon chain (C18)
seem to be recognized by EDG7, and there is no strict corre-
lation between the number of double bonds in the three octa-
decenoic acids (oleic (18:1), linoleic (18:2), and linolenic
(18:3)) and the potency of LPA for EDG7. It should also
be mentioned here that LPAs with polyunsaturated fatty
acyl chains, especially 2-linoleoyl LPA, are detected in ascites
from ovarian cancer patients and may account for the increas-
ing ability to activate ovarian cancer cell lines [8]. EDG7 is
expressed in human ovary [5] and to a high degree in many
ovary cancer cell lines (Bandoh, Aoki, Arai and Inoue, un-
published result), indicating a possible role of EDG7 in the
development of ovarian cancer. The literature indicates that
among the various biological activities of LPA, contraction of
smooth muscle cells [19], proliferation of cultured vascular
smooth muscle cells [17], and intracellular Ca2 mobilization
in A431 cells [15] are dependent on the length and degree of
unsaturation of fatty acids. These various responses can be
explained by the di¡erential expression of the three LPA re-
ceptors.
We showed in this study that EDG4 reacted with acyl-
LPAs and LPA analogs tested although lauroyl (12:0) LPA
was a very poor ligand for EDG4 (Fig. 2). Thus, it can be
concluded that EDG4 discriminates between 12:0 (lauroyl)
and 14:0 (myristoyl) LPAs. By contrast, the EDG2-EDG4
chimeric receptor seems to discriminate between 14:0 (myris-
toyl) and 16:0 (palmitoyl) LPAs (Fig. 5). Previously it has
been reported that both 1-oleoyl and 1-stearoyl LPA induce
EDG2-dependent cell rounding in EDG2-transfected neuronal
cells [3]. In addition, the ligand speci¢city of EDG2 using the
yeast pheromone response pathway was reported by Erickson
et al. They showed that LPAs with oleic (18:1), stearic (18:0),
or palmitic (16:0) acids, but not with capric (10:0) or caproic
(6:0) acids, activate EDG2 [22]. These results are in good
agreement with our results that LPA with both saturated
and unsaturated fatty acids are active against the EDG2-
EDG4 chimeric receptor and that it discriminates between
14:0 (myristoyl) and 16:0 (palmitoyl) LPAs.
Fig. 5. The activities of LPA and its structural analogs to induce increases in [Ca2]i in EDG2-EDG4-expressing Sf9 cells. EDG2-EDG4 chi-
meric receptor-expressing Sf9 cells, loaded with Fura-2 AM, were stimulated with 22 compounds of LPA and its analogs, and changes in
[Ca2]i were analyzed in CAF-110. The open and closed circles in A^K represent 1-acyl- and 2-acyl-LPA, respectively. A, Oleoyl (18:1, cis-v9-
octadecenoic acid); B, linoleoyl (18:2, cis,cis-v9,v12-octadecadienoic acid); C, linolenoyl (18:3, all cis-v9,v12,v15-octadecatrienoic acid); D,
arachidonoyl (20:4, all cis-v5,v8,v11,v14-eicosatetraenoic acid); E, lauroyl (12:0); F, myristoyl (14:0); G, palmitoyl (16:0); H, stearoyl (18:0);
I, elaidoyl (18:1, trans-v9-octadecenoic acid); J, palmitoleoyl (16:1, cis-v9-hexadecenoic acid); K, petroselinoyl (18:1, cis-v12-octadecenoic acid)
LPA. L, 1-O-alkyl (18:1, cis-v9-octadecenoic acid)-2-lyso-sn-glycero-3-phosphate (closed triangle) and 1-alkenyl-2-lyso-sn-glycero-3-phosphate
(alkenyl-GP) from bovine brain (open square).
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It has been reported that alkenyl-GP activates both EDG2
[22] and EDG4 [6] and that alkyl-GP activates EDG2 [22].
The present study con¢rmed that all LPA receptors belonging
to the EDG family can be activated by both alkyl- and alken-
yl-GP. This ligand speci¢city matches the type-3 LPA receptor
which Tigyi et al. classi¢ed according to their pharmacological
study [11,23,24]. In spite of this observation, we speculate that
the natural ligands for EDG2, EDG4, and EDG7 are acyl-
LPA rather than alkyl- or alkenyl-GP, because they were al-
ways shown to be weaker ligands than acyl-LPA for the three
LPA receptors. Interestingly, alkyl-GP was found to be con-
siderably more potent (about 30-fold) than the 1-acyl LPAs in
stimulating platelet aggregation [14] and producing cardiovas-
cular e¡ects in cats [25]. These results, together with our
present study, indicate that human platelets and carcinoma
cells express di¡erent LPA receptor(s) for platelet activation,
as suggested by Gueguen et al. [14].
The biological pathway for LPA formation remains to be
solved, although several studies indicate that the degradation
of phosphatidic acid by a phospholipase A, especially some
isoforms of phospholipase A2, may be involved in part [8,26^
28]. From the present study, it is easy to speculate that phos-
pholipase A1 activity may participate in the production of 2-
acyl LPA for EDG7 activation. So far, the description of
phospholipase A1 in mammals is still limited [29,30], and
further studies are necessary to elucidate the synthetic path-
way for 2-acyl-LPA.
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